Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
456
datasets available to search
ShareScore release 0.9.0
Dataset results
456 results for “mesothelioma”
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
ClinicalTrials.gov study NCT04153565. IPD Sharing: YES. Countries: 1. Publications: 1.
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
ClinicalTrials.gov study NCT03502746. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
ClinicalTrials.gov study NCT02899195. IPD Sharing: NO. Countries: 1. Publications: 2.
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
ClinicalTrials.gov study NCT00509041. IPD Sharing: Not stated. Countries: 1. Publications: 0.
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
ClinicalTrials.gov study NCT01098266. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT01064648. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
ClinicalTrials.gov study NCT01843374. IPD Sharing: YES. Countries: 19. Publications: 2.
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT02592551. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT03762018. IPD Sharing: NO. Countries: 6. Publications: 11.
Dataset related to article "Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice"
<p>This record contains data related to article "Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice"</p> <p>Malignant Pleural Mesothelioma (MPM) is an aggressive tumor of the pleural lining that is usually identified at advanced stages and resistant to current therapies. Appropriate pre-clinical mouse tumor models are of pivotal importance to study its biology. Usually, tumor cells have been injected intraperitoneally or subcutaneously. Using three available murine mesothelioma cell lines with different histotypes (sarcomatoid, biphasic, epithelioid), we have set up a simplified model of in vivo growth orthotopically by inoculating tumor cells directly in the thorax with a minimally invasive procedure. Mesothelioma tumors grew along the pleura and spread on the superficial areas of the lungs, but no masses were found outside the thoracic cavity. As observed in human MPM, tumors were highly infiltrated by macrophages and T cells. The luciferase-expressing cells can be visualized in vivo by bioluminescent optical imaging to precisely quantify tumor growth over time. Notably, the bioluminescence signal detected in vivo correctly matched the tumor burden quantified with classical histology. In contrast, the subcutaneous or intraperitoneal growth of these mesothelioma cells was considered either non-representative of the human disease or unreliable to precisely quantify tumor load. Our non-invasive in vivo model of mesothelioma is simple and reproducible, and it reliably recapitulates the human disease.</p>
Data from: Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma
Purpose: Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material is often an effusion and biochemical analysis of soluble markers may provide additional diagnostic information. This study aimed to establish a predictive model using biomarkers from pleural effusions, to allow early and accurate diagnosis. Patients and Methods: Effusions were collected prospectively from 190 consecutive patients at a regional referral centre. Hyaluronan, N-ERC/mesothelin, C-ERC/mesothelin, osteopontin, syndecan-1, syndecan-2, and thioredoxin were measured using ELISA and HPLC. A predictive model was generated and validated using a second prospective set of 375 effusions collected consecutively at a different referral centre. Results: Biochemical markers significantly associated with mesothelioma were hyaluronan (odds ratio, 95% CI: 8.82, 4.82–20.39), N-ERC/mesothelin (4.81, 3.19–7.93), CERC/mesothelin (3.58, 2.43–5.59) and syndecan-1 (1.34, 1.03–1.77). A two-step model using hyaluronan and N-ERC/mesothelin, and combining a threshold decision rule with logistic regression, yielded good discrimination with an area under the ROC curve of 0.99 (95% CI: 0.97–1.00) in the model generation dataset and 0.83 (0.74–0.91) in the validation dataset, respectively. Conclusions: A two-step model using hyaluronan and N-ERC/mesothelin predicts mesothelioma with high specificity. This method can be performed on the first available effusion and could be a useful adjunct to the morphological diagnosis of mesothelioma.
Large-scale human tissue analysis identifies Uroplakin 3B as a useful diagnostic marker for mesothelioma and normal meso-thelial cells
<p><strong>Supplement Figure 1:</strong> IHC validation by comparison of antibodies. Using MSVA-736M, an apical membranous Upk3b positivity is seen in mesothelial cells covering an appendix (A), amnion cells of a placenta (B), and umbrella cells of the renal pelvis urothelium (C), while staining is absent in adrenal gland (D). Using clone C362, a similar membranous staining is seen in mesothelial cells of the appendix (E), amnion cells (F), and urothelial umbrella cells (G) despite of a higher level of background staining. Clone C362 results in a significant nuclear staining of adrenocortical cells (H) which was not seen by MSVA-736M.</p>
Data from: Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: a retrospective study in a single center
In this study, we aimed to examine the clinical value of the pleural effusion (PE) biomarkers, soluble mesothelin-related peptide (SMRP), cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), and the utility of combining chest computed tomography (CT) findings with these biomarkers, in diagnosing malignant pleural mesothelioma (MPM). We conducted a retrospective cohort study in a single center. Consecutive patients with undiagnosed pleural effusions who underwent PE analysis between September 2014 and August 2016 were reviewed. This study included 240 patients (32 with MPM and 208 non-MPM). SMRP and the CYFRA 21-1/CEA ratio had a sensitivity and specificity for diagnosing MPM of 56.3% and 86.5%, and 87.5% and 74.0%, respectively. Using receiver operating characteristics (ROC) curve analysis of the ability of these markers to distinguish MPM from all other PE causes, the area under the ROC curve (AUC) for SMRP and the CYFRA 21-1/CEA ratio was 0.804 and 0.874, respectively. The sensitivity and specificity of SMRP combined with the CYFRA 21-1/CEA ratio were 93.8% and 64.9%, respectively. The sensitivity of the combination of SMRP, the CYFRA 21-1/CEA ratio, and the presence of Leung's criteria (a chest CT finding that is suggestive of malignant pleural disease) was 93.8%. In conclusion, the combined PE biomarkers had a high sensitivity for diagnosing MPM, although the addition of chest CT findings did not improve the sensitivity of SMRP combined with the CYFRA 21-1/CEA ratio. Combination of these biomarkers helped to rule out MPM effectively among patients at high risk of suffering MPM and would be valuable especially for old frail patients who have difficulty in undergoing invasive procedures such as thoracoscopy.
A WT1-positive pleural neoplasm. Is it always a mesothelioma? Diagnostic pitfall of WT1 immunohistochemistry in pleural neoplasm
Open the record for dataset details and reuse information.
A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
ClinicalTrials.gov study NCT01769547. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Mesothelioma and Radical Surgery 2
ClinicalTrials.gov study NCT02040272. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
ClinicalTrials.gov study NCT03875144. IPD Sharing: NO. Countries: 1. Publications: 7.
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
ClinicalTrials.gov study NCT00075699. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Mesothelioma Early Detection by VOCs
ClinicalTrials.gov study NCT04106973. IPD Sharing: NO. Countries: 1. Publications: 2.
DENdritic Cell Immunotherapy for Mesothelioma
ClinicalTrials.gov study NCT03610360. IPD Sharing: UNDECIDED. Countries: 5. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.